SAMHSA federal workplace drug testing panel: a complete guide for program administrators

The SAMHSA federal workplace drug testing panel is the mandatory standard that governs drug testing for federal employees and federally regulated industries — including DOT-covered transportation workers. Set by the Substance Abuse and Mental Health Services Administration (SAMHSA), the panel defines which substances must be screened, at what cutoff concentrations, and under what chain-of-custody procedures. If your organization is subject to federal testing mandates, understanding this panel is not optional — it determines what test you can use, how results must be verified, and what happens when a specimen is collected.

Private employers who are not subject to federal mandates can use broader or narrower panels, but many use the SAMHSA standard as a baseline because it is well-documented, widely recognized, and legally defensible.

What the SAMHSA mandatory panel includes

The SAMHSA federal panel is commonly called the "5-panel" because it targets five drug categories:

1. Marijuana (THC) — Screens for delta-9-tetrahydrocannabinol-9-carboxylic acid, the primary urine metabolite of cannabis.
2. Cocaine — Screens for benzoylecgonine, the major metabolite of cocaine.
3. Opiates — Covers morphine and codeine. At the confirmed positive stage, labs also test for heroin (6-AM) in certain circumstances.
4. Amphetamines — Covers amphetamine and methamphetamine. Confirmatory testing distinguishes between the two.
5. Phencyclidine (PCP) — Screens for the parent compound.

SAMHSA guidelines also require that semi-synthetic opioids — specifically oxycodone/oxymorphone and hydrocodone/hydromorphone — be added to the federal panel. Laboratories performing federally mandated testing must screen for these additional opioid analytes. This effectively makes the current federal panel broader than the classic five-substance list, so program administrators should confirm exactly which analytes their certified laboratory covers.

How the SAMHSA framework differs from non-regulated testing

Understanding what makes federal testing distinct helps you decide whether a given product or process fits your program:

• Chain of custody is mandatory. All federally mandated specimens must follow a documented chain-of-custody process from collection through laboratory analysis. Point-of-care instant tests cannot serve as the final result for a regulated federal test — they may be used for initial screening in limited contexts, but confirmation by a certified laboratory is required.
• HHS-certified laboratories only. Specimens collected under federal mandates must be analyzed by a laboratory certified under the HHS Mandatory Guidelines. Not every accredited laboratory qualifies; administrators must verify HHS certification specifically.
• Medical Review Officer (MRO) review is required. A licensed physician serving as MRO must review all laboratory results before they are reported to the employer. The MRO process allows donors to explain legitimate prescription use before a positive is finalized.
• Cutoff concentrations are federally specified. SAMHSA/HHS publishes exact initial and confirmatory cutoff concentrations. Administrators cannot lower or raise these cutoffs for a federally mandated test. For a detailed look at how cutoffs work, see our guide on drug test cutoff levels explained.
• Specimen type matters. The HHS Mandatory Guidelines specify approved specimen types — urine is the primary matrix. Oral fluid testing has been added as an approved alternative under updated guidelines, but procedures differ from urine collection.

Step-by-step: determining whether SAMHSA rules apply to your program

1. Identify your regulatory authority. Federal employees are covered by Executive Order 12564 and the Federal Workplace Drug Testing Programs. Private employers in DOT-regulated industries (FMCSA, FAA, FRA, FTA, PHMSA, USCG) are governed by 49 CFR Part 40, which incorporates HHS/SAMHSA standards. If neither applies, you are a non-regulated employer.
2. Confirm which substances you must screen. If regulated, you are bound to the current HHS Mandatory Guidelines panel. If non-regulated, you can expand or customize your panel.
3. Select a collection site that understands federal procedures. Chain-of-custody forms, split-specimen collection, and tamper-evident packaging are non-negotiable for regulated tests.
4. Contract with an HHS-certified lab. Verify current HHS certification directly — certification status can change.
5. Engage a qualified MRO. The MRO must be a licensed physician who has completed MRO training and holds current MRO certification.
6. Choose a Substance Abuse Professional (SAP) if needed. If an employee violates the drug testing policy, SAP evaluation is required before return-to-duty testing.

Common mistakes program administrators make

• Assuming an instant cup test satisfies a federal mandate. Point-of-care tests are valuable screening tools for non-regulated programs but cannot replace HHS-certified lab confirmation and MRO review for regulated testing.
• Using a non-certified laboratory. A lab can be CAP-accredited or state-licensed without being HHS-certified. These are different credentials.
• Applying the classic 5-panel without the semi-synthetic opioid additions. The current federal panel is broader than many administrators realize. Verify your lab's analyte list against the current HHS Mandatory Guidelines.
• Ignoring panel expansion options for non-regulated programs. If you are a private employer not subject to federal mandates, limiting yourself to only the five classic substances may miss substances — such as fentanyl, benzodiazepines, or synthetic cannabinoids — that are relevant to workplace safety in your industry.
• Misunderstanding detection windows. No substance has a single fixed detection window. Detection times vary by individual metabolism, dose, frequency of use, hydration, and the cutoff concentration used. Communicate this variability clearly to supervisors and HR.

Instant tests and the SAMHSA panel: where they fit

For non-regulated employers, instant point-of-care tests that screen for the same five (or expanded) substance categories can support pre-employment screening, reasonable suspicion testing, and return-to-duty monitoring — especially when speed and on-site convenience matter. Understanding regulatory designations like 510(k) clearance and Employment & Insurance (E&I) classification helps you select a test appropriate for administrative decision-making rather than clinical diagnosis. Our guide on CLIA waived vs. 510(k) and other drug test designations explains each classification in plain language.

Non-regulated employers who want to go beyond the SAMHSA 5-panel often add substances such as benzodiazepines, oxycodone, buprenorphine, or fentanyl to address their specific workforce risks. Comparing panel options before purchasing is an important step. See our 5-panel vs. 10-panel vs. 12-panel comparison for a structured breakdown.

Recommended products for workplace screening programs

Whether you are running a non-regulated workplace program aligned with the SAMHSA substances or need supplemental screening tools, the following Magenta collections cover the most common administrative configurations:

• 5-panel drug tests — Matches the classic SAMHSA substance categories for baseline workplace screening.
• 10-panel drug tests — Adds benzodiazepines, barbiturates, methadone, methaqualone, and propoxyphene to the SAMHSA core — common in safety-sensitive environments.
• 12-panel drug tests — Extends coverage to include oxycodone and buprenorphine, addressing prescription opioid misuse.
• Drug test cups — Integrated collection and testing in a single device; practical for high-volume or on-site programs.
• Drug test dip cards — Flexible multi-analyte strips suited for programs that collect and test in separate workflows.
• Best drug tests for workplace screening — A curated comparison to help you select the right format for your program.

For DOT-regulated employers, see our dedicated resource on best drug tests for DOT-industry employer screening.